Introduction: Hepatocellular carcinoma (HCC) is the most common primary liver cancer, characterized by high mortality rate. In clinical practice, several makers of liver cancer, such as VEGFR1, FGFR1 and PDGFR alpha, were identified and their potentials as a therapeutic target were explored. However, the unsatisfied treatment results emphasized the needs of new therapeutic targets.Methods: 112 HCC patients samples were obtained to evaluate the expression of LRRC41, SOX9, CD44, and EPCAM in HCC, combined with prognosis analysis. A DEN-induced HCC rat model was constructed to verify the expression of LRRC41 and SOX9 in HCC and lung metastasis tissues. Immune score evaluation was analysized by bioinformatics methods. Network pharmacology was performed to explored the potential FDA-approved drugs targeting LRRC41.Results: Through analysis of the Timer database and tissue micro-array, we confirmed that LRRC41 was over-expressed in HCC and exhibited a significant positive correlation with recurrence and metastasis. Immunohistochemistry staining of human HCC tissue samples revealed significant upregulation of LRRC41, SOX9, CD44, and EPCAM, with LRRC41 showing a positive correlation with SOX9, CD44, and EPCAM expression. UALCAN database analysis indicated that LRRC41 and SOX9 contribute to poor prognosis whereas CD44 and EPCAM did not demonstrate the same significance. Furthermore, analysis of a DEN-induced HCC rat model confirmed the significantly elevated expression of LRRC41 and SOX9 in HCC and lung metastasis tissues. Drug sensitivity analysis and molecular docking targeting LRRC41 identified several FDA-approved drugs, which may have potential antitumor effects on HCC by targeting LRRC41.Conclusion: Our findings highlight the role of LRRC41 overexpression in promoting HCC progression and its association with a poor prognosis. Drug sensitivity analysis and molecular docking shows several FDA-approved drugs may be potential therapeutic targets for HCC. Targeting LRRC41 may hold promise as a potential therapeutic strategy for HCC.
基金：
Open Project of Key Laboratory of Shanghai Municipal Health Commission [ZDSYS-2021-06]; National Natural Science Foundation of China [82103058]; Shanghai Municipal Health and Family Planning Commission Foundation [20214Y036]
第一作者机构：[1]Tongji Univ, Inst Biomed Engn & Nano Sci, Sch Med, Shanghai, Peoples R China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Li Jun,Qin Chenjie,Wu Yicheng,et al.Targeting LRRC41 as a potential therapeutic approach for hepatocellular carcinoma[J].FRONTIERS IN MOLECULAR BIOSCIENCES.2023,10:doi:10.3389/fmolb.2023.1300294.
APA：
Li, Jun,Qin, Chenjie,Wu, Yicheng,Cheng, Sheng,Wang, Yuanqing...&Li, Jutang.(2023).Targeting LRRC41 as a potential therapeutic approach for hepatocellular carcinoma.FRONTIERS IN MOLECULAR BIOSCIENCES,10,
MLA：
Li, Jun,et al."Targeting LRRC41 as a potential therapeutic approach for hepatocellular carcinoma".FRONTIERS IN MOLECULAR BIOSCIENCES 10.(2023)
